NO synthase inhibition increases aldosterone in humans

Hypertension

Volumn 44, Issue 5, 2004, Pages 739-745

  Muldowney III, James A S ^a   Davis, Stephen N ^a   Vaughan, Douglas E ^a,b   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Angiotensin converting enzyme; Arginine; Nitric oxide

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PLACEBO; POTASSIUM; RAMIPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HEART RATE; HUMAN; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

ADULT; ALDOSTERONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARGININE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POTASSIUM; RAMIPRIL; RENIN;

EID: 7244231097     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000143852.48258.f1     Document Type: Article

References (31)

1. Heitzer T, Schlinzig T, Krohn K Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
2. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
3. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 1997;10:1326-1334.
4. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
5. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
6. Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart. 2002;88:475-480.
7. Natarajan R, Lanting L, Bai W, Bravo EL, Nadler J. The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells. J Steroid Biochem Mol Biol. 1997;61:47-53.
8. Hanke CJ, Drewett JG, Myers CR, Campbell WB. Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect. Endocrinology. 1998;139:4053-4060.
9. Kreklau EL, Carlson EJ, Drewett JG. Nitric oxide inhibits human aldosteronogenesis without guanylyl cyclase stimulation. Mol Cell Endocrinol. 1999;153:103-111.
10. Rocha R, Stier CTJ, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
11. Oestreicher EM, Martinez-Vasquez D, Stone JR, Jonasson L, Roubsanthisuk W, Mukasa K, Adler GK. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation. 2003;108:2517-2523.
12. Usui M, Ichiki T, Katoh M, Egashira K, Takeshita A. Regulation of angiotensin II receptor expression by nitric oxide in rat adrenal gland. Hypertension. 1998;32:527-533.
13. Simmons JC, Freeman RH. L-arginine analogues inhibit aldosterone secretion in rats. Am J Physiol. 1995;268:R1137-R1142.
14. Cachofeiro V, Fortepiani LA, Nararro-Cid J, Lahera V, Garcia-Estan J. Renal dysfunction after chronic blockade of nitric oxide synthesis. Antioxid Redox Signal. 2002;4:885-891.
15. Salemi R, McDougall JG, Hardy KJ, Wintour EM. Local inhibition of nitric oxide temporarily stimulates aldosterone secretion in conscious sheep in vivo. Am J Physiol Endocrinol Metab. 2001;280:E584-E590.
16. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
17. Davidson NC, Struthers AD. Nitric oxide regulates renin release during salt depletion but does not alter angiotensin responses in normal humans. J Cardiovasc Pharmacol Ther. 1999;4:9-14.
18. Nithipatikom K, Holmes BB, McCoy MJ, Hillard CJ, Campbell WB. Chronic administration of nitric oxide reduces angiotension II receptor type I expression and aldosterone synthesis in zona glomerulosa cells. Am J Physiol Endocrinol Metab. 2004.
19. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258-265.
20. Sander M, Chavoshan B, Victor RG. A large blood pressure-raising effect of nitric oxide synthase inhibition in humans. Hypertension. 1999;33: 937-942.
21. Broere A, Van Den Meiracker AH, Boomsma F, Derkx FH, Veld AJ, Schalekamp MA. Human renal and systemic hemodynamic, natriuretic, and neurohumoral responses to different doses of L-NAME. Am J Physiol. 1998;275:F870-F877.
22. Pfeiffer S, Leopold E, Schmidt K, Brunner F, Mayer B. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement for bioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996;118:1433-1440.
23. Perinotto P, Biggi A, Carra N, Orrico A, Valmadre G, Dall'Aglio P, Novarini A, Montanari A. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. J Am Soc Nephrol. 2001;12:1706-1712.
24. Kawamura M, Imanashi M, Matsushima Y, Ito K. Hiramori K. Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin Exp Pharmacol Physiol. 1992;19:547-553.
25. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
26. Volpi R, Chiodera P, Caffarri G, Vescovi PP, Capretti L, Gatti C, Coiro V. Influence of nitric oxide on hypoglycemia-or angiotensin II-stimulated ACTH and GH secretion in normal men. Neuropeptides. 1996;30:528-532.
27. Wang T. Role of iNOS and eNOS in modulating proximal tubule transport and acid-base balance. Am J Physiol Renal Physiol. 2002;283:F658-F662.
28. Barnes JN, Drew PJ, Furniss SS, Holly JM, Knight AR, Skehan JD, Goodwin FJ. Effect of angiotensin converting-enzyme inhibition on potassium-mediated aldosterone secretion in essential hypertension. Clin Sci (Lond). 1985;68:625-630.
29. Griffith OW, Gross SS. Inhibitors of nitric oxide synthases. In: Feelisch M, Stamler JS. eds. Methods in Nitric Oxide Research. New York, NY: John Wiley and Sons; 1996:187-209.
30. Prasad A, Husain S, Quyyumi AA. Effect of enalaprilat on nitric oxide activity in coronary artery disease. Am J Cardiol. 1999;84:1-6.
31. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.